MDWD · MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Market Cap
161.9M
52 Wk Range
$12.42 - $20.03
Previous Close
$12.42
Open
$12.42
Volume
92,645
Day Range
$12.42 - $13.15
Enterprise Value
150.4M
Cash
35.34M
Avg Qtr Burn
-9.127M
Insider Ownership
16.71%
Institutional Own.
55.88%
Qtr Updated
Jun 30th 2026
